跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

VENUS REMEDIES LIMITED

首页临床试验发起方与机构VENUS REMEDIES LIMITED

VENUS REMEDIES LIMITED

SCB INDUSTRIAL ESTATE CHD LDH OVERSEAS, Ludhiana, Punjab, 印度

别名:

VENUS

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

21

1 进行中

药物批准

98

批准总数

监管机构

3

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

3 期

11

52.4%

1 期

3

14.3%

4 期

2

9.5%

Unknown

2

9.5%

不适用

1

4.8%

1/2 期

1

4.8%

试验状态分布

已完成

14

66.7%

尚未招募

1

4.8%

招募中

5

23.8%

相关临床试验

该机构主办的试验（21）

A clinical study to compare the safety of VRP-034 (A Novel Formulation of Polymyxin B) against commercially available polymyxin B medicine, and their effects on the kidney.

Mar 202648 名受试者

Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects

Feb 202124 名受试者

CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria

Jan 2014230 名受试者

A Randomized, Doubleâ€blind, Doubleâ€dummy, Activeâ€controlled, Multiâ€centre Trial on Infections (respiratory and urinary infections) Caused by Î² â€“ Lactamase (ESBL and MBL) producing Gram Negative Bacteria

Dec 2013348 名受试者

To assess the safety and tolerability of ELORES

Aug 201312 名受试者

CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF VRP 1620 IN PATIENTS OF BREAST CANCER.

Aug 2013220 名受试者

An observational and multicentric post marketing surveillance study to evaluate the efficacy and safety of Elores in patients with various bacterial infection

Mar 20132500 名受试者

A post marketing surveillance study to evaluate safety and efficacy of fixed dose combination of Ceftriaxone + Sulbactam (Sulbactomax) in patients with various bacterial infections

Mar 20112500 名受试者

第 1 页，共 3 页

药物批准

按机构分类的批准

PHILIPPINES

Philippines FDA

55

药物批准

SFDA

Saudi Food and Drug Authority

21

药物批准

NPRA

National Pharmaceutical Regulatory Agency

22

药物批准

近期批准

VENMERO Meropenem Powder for solution for injection or infusion USP 500mg

VENMERO Meropenem Powder for solution for injection or infusion USP 1000mg

VENDA Bendamustine Hydrochloride 100mg Powder for Concentrate for Solution for Infusion

OXOL Oxaliplatin Concentrate for Solution for Infusion 5mg/ml

CITABOL (Gemcitabine Powder for Solution for Infusion 200 mg/vial)

ROBOL (Doxorubicin Concentrate for Solution for Infusion 2mg/ml)

PLATOL (Cisplatin Concentrate for solution for Infusion 50mg/50mL)

IRINOL (IRINOTECAN CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML)

TREXOL - Methotrexate Solution for Injection 100 mg/ml

Lastinem-500 (Imipenem and Cilastatin Powder for Solution for Infusion 500 mg/ 500mg)

资讯

暂无资讯文章

本页目录

概览
相关临床试验21
药物批准98
资讯

返回机构列表